GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) for Various Vascular Indications Registry

This study focuses on observing patients treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX), a special type of stent. The stent is used for various conditions such as Iliac, Superficial Femoral Artery (SFA), Superficial Femoral Artery In-stent restenosis (SFA ISR), Hemodialysis access (AV access), Visceral artery aneurysms (VAA), Trauma/Injury, Popliteal Artery Aneurysms (PAA), or Other. The study involves around 35 sites in Europe and aims to enroll a minimum of 614 patients. Its main goal is to gather real-world data on the stent's performance and safety in these diverse applications, potentially improving treatment strategies for these conditions. During the study, participants will be followed for varying periods depending on their condition, ranging from one year for Trauma/Injury and other conditions, up to ten years for Popliteal Artery Aneurysms (PAA). The primary outcome measured is the freedom from device-related serious adverse events (SAE). This means the study will track whether any significant issues occur that are directly related to the use of the stent. The study will assess these outcomes based on the investigator's evaluation.